Senior management changes at ViiV Healthcare and GSK

5 December 2016

After seven years as chief executive of ViiV Healthcare, Dr Dominique Limet will step down at the end of March 2017. ViiV Healthcare is majority-owned by UK pharma major GlaxoSmithKline (LSE: GSK) in partnership with Pfizer and Shionogi.

Deborah Waterhouse, currently senior vice president Primary Care, GSK US Pharmaceuticals, will succeed him, and will take up the CEO designate role on January 2017.

Dr Limet started his career as a General Practitioner in France. He joined GSK in 1996 from Ciba Geigy, where he held various marketing and management positions. In 2000, He was appointed general manager of GSK France. He then became senior vice president, Southern & Eastern Europe area director and then head of GSK personalized medicine strategy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK